---
layout: default
title: Tinidazole
parent: Model Prediction Only (L5)
nav_order: 1229
evidence_level: L5
indication_count: 10
---

# Tinidazole
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Tinidazole: From Anti-Infective Therapy to Postmenopausal Atrophic Vaginitis

## One-Sentence Summary

Tinidazole is a 5-nitroimidazole anti-infective active against anaerobic bacteria and protozoa such as Trichomonas, Giardia and Entamoeba.
The TxGNN model predicts it may be effective for **postmenopausal atrophic vaginitis**,
but **0 clinical trials** and **0 publications** currently support this direction, so the prediction rests on the model alone.

## Quick Overview

| Item | Content |
|------|------|
| Predicted New Indication | Postmenopausal atrophic vaginitis |
| TxGNN Prediction Score | 99.93% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 11 (generic ANDA approvals) |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, tinidazole is a 5-nitroimidazole antimicrobial. Its activity against anaerobes, protozoa and bacterial vaginosis pathogens is well established. Mechanistically, though, the link to the new indication is weak.

Atrophic vaginitis after menopause is driven mainly by estrogen deficiency, not by infection. An anti-infective has no clear disease-modifying role in it. The very high graph score most likely reflects the many vaginal-infection diseases neighbouring tinidazole in the knowledge graph, not a real therapeutic relationship.

The other top-ranked predictions (vulvar ulceration, vulvar neoplasm, benign breast conditions) show the same pattern of genital-tract or breast graph proximity without supporting evidence. The one exception is AIDS (rank 5), which has indirect evidence: tinidazole treats co-infections common in people with HIV, and one trial explores microbiome modulation for HIV susceptibility. This evidence does not show that tinidazole treats AIDS itself.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available.

## US Market Information

| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---------|------|------|-----------|
| ANDA202044 | Tinidazole | Film-coated tablet | Chartwell RX, LLC |
| ANDA202489 | Tindazole | Film-coated tablet | Rising Pharma Holdings, Inc. |
| ANDA203808 | Tinidazole | Tablet | Edenbridge Pharmaceuticals LLC. |

All listed products are oral tablets.

## Safety Considerations

Please refer to the package insert for safety information.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction has no clinical trial or literature support (Evidence Level L5). The mechanistic link is weak, because atrophic vaginitis is estrogen-deficiency driven and not infectious. The high score likely reflects knowledge-graph proximity to vaginal infections.

**To proceed, the following is needed:**
- FDA package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data from DrugBank
- Any preclinical or clinical evidence for tinidazole in atrophic vaginitis, and a comparison with established estrogen-based treatments
- Route compatibility assessment, since no route information has been evaluated for this indication
- Consider re-prioritizing to the AIDS-related prediction (Evidence Level L4), which has indirect co-infection and microbiome evidence

*This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any application.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

